A novel drug, apitegromab, has demonstrated potential in preserving lean muscle mass for individuals experiencing rapid weight loss, a common side effect associated with the increasing use of weight-loss medications often referred to as ‘slimming jabs.’ These medications, including GLP-1 receptor agonists like tirzepatide, have proven highly effective in promoting weight reduction but can also lead to the loss of valuable muscle tissue.
Research, including a randomized, double-blind, placebo-controlled Phase 2 trial published in Nature, investigated the effects of apitegromab on lean mass preservation during tirzepatide-induced weight loss. The findings suggest that apitegromab could offer a solution to a significant challenge faced by many patients seeking to manage obesity and its associated health risks.
Understanding the Challenge of Muscle Loss
Weight loss, especially when achieved rapidly through pharmacotherapy, often results in a reduction of both fat mass and lean body mass. Lean mass includes muscles, bones, and organs. While reducing fat is the primary goal for health benefits, the loss of muscle mass can have detrimental consequences. Reduced muscle strength can impact physical function, increase the risk of falls and fractures, and potentially slow down metabolism, making it harder to maintain weight loss in the long term. This phenomenon has been colloquially termed ‘Ozempic butt’ in media reports, referring to the loss of gluteal muscle mass.
GLP-1 receptor agonists, such as semaglutide (found in Ozempic and Wegovy) and tirzepatide (found in Mounjaro and Zepbound), work by mimicking natural hormones that regulate appetite and blood sugar. They promote feelings of fullness and slow gastric emptying, leading to reduced calorie intake and subsequent weight loss. However, this appetite suppression can also affect muscle protein synthesis and increase muscle breakdown if not counteracted.
Apitegromab’s Potential Role
Apitegromab is a drug designed to target and activate muscle stem cells, promoting muscle growth and repair. By potentially stimulating the body’s natural muscle-building processes, it aims to offset the muscle catabolism that can occur during calorie restriction and weight loss. The Phase 2 trial specifically examined whether co-administering apitegromab with tirzepatide could mitigate the loss of lean tissue compared to a placebo.
While the full details of the trial’s efficacy and safety profile are being analyzed and published, early indications suggest that apitegromab could be a valuable adjunct therapy for individuals on potent weight-loss medications. This could allow patients to achieve their weight loss goals more effectively while preserving crucial muscle mass, thereby supporting overall metabolic health and physical function.
Future Implications and Research
The development of therapies like apitegromab highlights a growing understanding of the complex physiological changes associated with modern obesity treatments. As these weight-loss drugs become more widely prescribed, addressing side effects like muscle loss is becoming increasingly important for comprehensive patient care. Further research, including larger Phase 3 trials, will be necessary to confirm the long-term benefits and safety of apitegromab in diverse patient populations. If successful, apitegromab could represent a significant advancement in the field of obesity management, offering a more holistic approach to improving health outcomes.
Mitchell Landsberg is the senior reporter for News Raise and focuses on Technology. Mitchell regularly writes about social media platforms and how influencers, industry and general people use them to communicate and make money.
